Effect of Stromal-cell-derived Factor 1 on Stem-cell Homing and Tissue Regeneration in Ischaemic Cardiomyopathy
Overview
Authors
Affiliations
Background: Myocardial regeneration via stem-cell mobilisation at the time of myocardial infarction is known to occur, although the mechanism for stem-cell homing to infarcted tissue subsequently and whether this approach can be used for treatment of ischaemic cardiomyopathy are unknown. We investigated these issues in a Lewis rat model (ligation of the left anterior descending artery) of ischaemic cardiomyopathy.
Methods: We studied the effects of stem-cell mobilisation by use of granulocyte colony-stimulating factor (filgrastim) with or without transplantation of syngeneic cells. Shortening fraction and myocardial strain by tissue doppler imaging were quantified by echocardiography.
Findings: Stem-cell mobilisation with filgrastim alone did not lead to engraftment of bone-marrow-derived cells. Stromal-cell-derived factor 1 (SDF-1), required for stem-cell homing to bone marrow, was upregulated immediately after myocardial infarction and downregulated within 7 days. 8 weeks after myocardial infarction, transplantation into the peri-infarct zone of syngeneic cardiac fibroblasts stably transfected to express SDF-1 induced homing of CD117-positive stem cells to injured myocardium after filgrastim administration (control vs SDF-1-expressing cardiac fibroblasts mean 7.2 [SD 3.4] vs 33.2 [6.0] cells/mm2, n=4 per group, p<0.02) resulting in greater left-ventricular mass (1.24 [0.29] vs 1.57 [0.27] g) and better cardiac function (shortening fraction 9.2 [4.9] vs 17.2 [4.2]%, n=8 per group, p<0.05).
Interpretation: These findings show that SDF-1 is sufficient to induce therapeutic stem-cell homing to injured myocardium and suggest a strategy for directed stem-cell engraftment into injured tissues. Our findings also indicate that therapeutic strategies focused on stem-cell mobilisation for regeneration of myocardial tissue must be initiated within days of myocardial infarction unless signalling for stem-cell homing is re-established.
Dutta S, Zhu Y, Almuntashiri S, Peh H, Zuniga J, Zhang D Am J Physiol Lung Cell Mol Physiol. 2024; 328(1):L60-L74.
PMID: 39585242 PMC: 11905806. DOI: 10.1152/ajplung.00104.2024.
Zoledronate interrupts pre-osteoclast-induced angiogenesis via SDF-1/CXCR4 pathway.
Awad M, Taylor-Diaz E, Tawfik A, Hussein K, Elmansi A, Elashiry M Bone Rep. 2024; 23:101812.
PMID: 39583183 PMC: 11585646. DOI: 10.1016/j.bonr.2024.101812.
Regenerative medicine in cardiovascular disease.
Goto T, Nakamura Y, Ito Y, Miyagawa S Regen Ther. 2024; 26:859-866.
PMID: 39430582 PMC: 11490749. DOI: 10.1016/j.reth.2024.09.004.
Cellular regenerative therapy in stress urinary incontinence: new frontiers?-a narrative review.
Andersson K, Williams K Transl Androl Urol. 2024; 13(8):1709-1716.
PMID: 39280677 PMC: 11399031. DOI: 10.21037/tau-22-682.
Healing the Ischaemic Heart: A Critical Review of Stem Cell Therapies.
Tonkin D, Yee-Goh A, Katare R Rev Cardiovasc Med. 2024; 24(4):122.
PMID: 39076280 PMC: 11273058. DOI: 10.31083/j.rcm2404122.